Alkermes (ALKS) Debt Ratio (2011 - 2026)

Alkermes (ALKS) posted quarterly Debt Ratio of 0.34 for Q2 2026, down 3.54% quarter-over-quarter from 0.35 in Q1 2026.

Alkermes (ALKS) Debt Ratio (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Debt Ratio for 15 consecutive years, with 0.34 the latest figure, recorded in Q2 2026.

In Q2 2026, Debt Ratio changed N/A year-over-year to 0.34; the TTM figure through Jun 2026 stood at 0.34 (changed N/A YoY), while the FY2023 annual figure was 0.14, down 8.86% from the prior year.
Debt Ratio eased to 0.34 in Q2 2026 per ALKS's latest filing, from 0.35 in the prior quarter.
Across five years, Debt Ratio topped out at 0.35 in Q1 2026 and bottomed at 0.13 in Q3 2023.
Historically, Debt Ratio has averaged 0.17 across 4 years, with a median of 0.15 in 2022.
Annual changes were most pronounced in 2023 — Debt Ratio fell 15.54% — and 2024, when it increased 4.83%.
Alkermes' Debt Ratio stood at 0.15 in 2022, then retreated by 8.86% to 0.14 in 2023, then declined by 1.53% to 0.13 in 2024, then soared by 155.32% to 0.34 in 2026.
Business Quant data shows ALKS's Debt Ratio at 0.34 in Q2 2026, 0.35 in Q1 2026, and 0.13 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	0.42
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.32
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	0.12
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	0.34

Download Data